	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
MULTIPLE MYELOMA (MM)					
REVLIMID® (lenalidomide)	Relapsed/refractory				
	Newly diagnosed				
	Maintenance				
POMALYST®/IMNOVID® (US/EU) (pomalidomide)	Relapsed/refractory				
THALOMID®/Thalidomide Celgene® (US/EU) (thalidomide)	Newly diagnosed				
IMFINZI™ (durvalumab)[a]	Relapsed/refractory, newly diagnosed				
CC-122					
BCMA CAR-T (bb2121)[b]					
CC-220	Relapsed/refractory				
Citarinostat (ACY-241)	Relapsed/refractory				
MYELODYSPLASTIC SYNDROMES (MDS)					
VIDAZA® (azacitidine for injection)					
REVLIMID® (lenalidomide)	Deletion 5q				
CC-486	Lower-risk				
	Post hypomethylating agent (HMA) failure				
Luspatercept (ACE-536)[c]					
IMFINZI™ (durvalumab)[a]	Post HMA failure				
Anti-CD47 Antibody: CC-90002					
ACUTE MYELOID LEUKEMIA (AML)					
VIDAZA® (azacitidine for injection)	AML (20%-30% blasts) (EU)				
	AML (>30% blasts) (EU)				
CC-486	Post-induction AML maintenance				
IDHIFA® (enasidenib)[d]	Relapsed/refractory IDH2 mutation (US)				
Pan-IDH Inhibitor: AG-881[d]					
IMFINZI™ (durvalumab)[a]					
Anti-CD47 Antibody: CC-90002					
CC-90009					

[a]In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC. AstraZeneca [b]In collaboration with bluebird bio, Inc. bluebirdbio

[c]In collaboration with Acceleron Pharma, Inc. ACCELERON [d]In collaboration with Agios Pharmaceuticals, Inc. agios

MedImmune

REVLIMID®, POMALYST®, IMNOVID®, THALOMID®, Thalidomide Celgene®, VIDAZA®, and IDHIFA® are registered trademarks of Celgene Corporation.

IMFINZI™ is a trademark of AstraZeneca group of companies.

Celgene

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

© 2017 Celgene Corporation 08/17

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
LYMPHOMA					
REVLIMID® (lenalidomide)	Mantle cell lymphoma: Relapsed/refractory	■	■	■	■
	Diffuse large B-cell lymphoma (ABC subtype): First-line	■	■	■	
	Indolent lymphoma: Relapsed/refractory	■	■	■	
	Follicular lymphoma: First-line	■	■	■	
	Adult T-cell leukemia-lymphoma (Japan)	■	■	■	■
ISTODAX® (romidepsin) for injection	Cutaneous T-cell lymphoma (US)[a]	■	■	■	■
	Peripheral T-cell lymphoma: Relapsed/refractory[a]	■	■	■	■
	Peripheral T-cell lymphoma: First-line	■	■	■	
CC-122	Diffuse large B-cell lymphoma	■			
	Indolent lymphoma: Relapsed/refractory	■			
CC-486	Diffuse large B-cell lymphoma	■			
IMFINZI™ (durvalumab)[b]	Non-Hodgkin lymphoma (NHL)	■			
CD19 CAR-T (JCAR017)[c]	Aggressive large B-cell lymphoma: Relapsed/refractory	■			
Anti-CD47 Antibody: CC-90002	Non-Hodgkin lymphoma (NHL)	■			
CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)					
CC-122		■			
IMFINZI™ (durvalumab)[b]		■			
BETA-THALASSEMIA					
Luspatercept (ACE-536)[d]		■	■	■	
MYELOFIBROSIS					
Luspatercept (ACE-536)[d]		■	■		

[a]Filing for regulatory approval based on pivotal phase 2 data. [b]In collaboration with MedImmune Limited, a wholly owned subsidiary of AstraZeneca PLC. AstraZeneca MedImmune

[c]In collaboration with Juno Therapeutics. juno Celgene has commercial rights outside of North America and China.

[d]In collaboration with Acceleron Pharma, Inc. ACCELERON

REVLIMID® and ISTODAX® are registered trademarks of Celgene Corporation. IMFINZI™ is a trademark of AstraZeneca group of companies.

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

© 2017 Celgene Corporation 08/17

SOLID TUMORS

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) (US)/ (paclitaxel formulated as albumin-bound nanoparticles) (EU)	Breast: Metastatic	■	■	■	■
	Non-small cell lung: Advanced (first-line)	■	■	■	■
	Pancreatic: Metastatic (first-line)	■	■	■	■
	Pancreatic: Adjuvant	■	■	■	
	Gastric: Metastatic (Japan)[a]	■	■	■	■
CC-486	Breast: Metastatic	■	■		
	Non-small cell lung: Advanced	■	■		
Marizomib	Glioblastoma	■	■		
CC-122	Hepatocellular carcinoma	■			
Anti-CD47 Antibody: CC-90002		■			
Pan-IDH Inhibitor: AG-881[b]	Glioma	■			
LSD1 Inhibitor: CC-90011		■			

[a]Trial conducted by licensee partner, Taiho Pharmaceuticals Co. Ltd. [b]In collaboration with Agios Pharmaceuticals, Inc. agios

ABRAXANE® is a registered trademark of Celgene Corporation.

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

© 2017 Celgene Corporation 08/17

	Area of Research	Phase 1	Phase 2	Phase 3	Post-Approval Research
INFLAMMATION & IMMUNOLOGY					
OTEZLA® (apremilast)	Psoriatic arthritis (PsA)	■	■	■	■
	Psoriasis	■	■	■	■
	Ankylosing spondylitis	■	■	■	
	Behçet's disease	■	■	■	
	Ulcerative colitis	■	■		
Mongersen (GED-0301)	Crohn's disease	■	■	■	
	Ulcerative colitis	■	■		
Ozanimod	Relapsing multiple sclerosis	■	■	■	
	Ulcerative colitis	■	■	■	
	Crohn's disease	■	■		
ABX-1431[a]	Neuroinflammation	■			
RPC4046	Eosinophilic esophagitis	■	■		
CC-220	Systemic lupus erythematosus	■	■		
CC-90001	Idiopathic pulmonary fibrosis	■	■		
CC-90006	Autoimmune disorders	■			
CELLULAR THERAPIES					
PDA-002	Diabetic foot ulcers	■	■		
	Diabetic peripheral neuropathy	■	■		
PNK-007	AML	■			
	MM	■			

[a]In collaboration with Abide Therapeutics.

OTEZLA® is a registered trademark of Celgene Corporation.

Celgene

For information on approved uses, please refer to approved product labeling. Post-approval research includes Celgene-sponsored and Celgene-supported studies.

The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.

© 2017 Celgene Corporation 08/17